{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:00:47Z","timestamp":1790676047650,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood-based biomarkers (BBMs) are rapidly reshaping the diagnostic and translational landscape of Alzheimer\u2019s disease (AD), offering a scalable alternative to cerebrospinal fluid (CSF) assays and positron emission tomography (PET). This paper aims to conduct bibliometric analysis on the hotspots and trends in this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications addressing AD-related blood\/plasma\/serum biomarkers from 1 January 2011 to 29 November 2025 were retrieved from the Web of Science Core Collection (WoSCC) and Scopus. Only English-language articles and reviews were included. VOSviewer, CiteSpace, and the R package bibliometrix were used to evaluate publication trends, collaboration networks (countries, institutions, authors), co-cited journals and references, and keyword evolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,771 publications with 53,568 citations were included. Annual output rose steadily and accelerated after 2018, while 2025 records covered approximately the first 11\u202fmonths of the year. The USA (795 publications) and China (478) were the most productive countries, whereas the UK and Sweden showed strong citation impact and collaboration intensity. The University of Gothenburg (263) and Sahlgrenska University Hospital (237) were the leading institutions. Henrik Zetterberg (218) and Kaj Blennow (185) were the most prolific authors. Co-citation analysis identified the NIA\u2013AA biological research framework and validation studies of plasma amyloid-beta (A\u03b2) and plasma phosphorylated tau (p-tau) as the intellectual base. Keyword and burst analyses indicated a clear shift from early themes (e.g., proteomics and oxidative stress) toward clinically oriented topics, including plasma p-tau217\/p-tau181, diagnostic performance, and implementation recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Research on AD BBMs has entered a phase of rapid growth and clinical translation. Plasma phosphorylated tau (especially p-tau217) is the leading biomarker for detecting AD-specific pathology. Plasma A\u03b2 ratios play a supportive role in amyloid triage, while neurodegeneration (NfL) and astroglial (GFAP) markers provide complementary information for prognosis and monitoring. Future priorities include real-world implementation, assay standardization, and integration of multi-marker panels into biological diagnostic\/staging frameworks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1886781","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:10Z","timestamp":1790673910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global research trends and hotspots in blood-based biomarkers for Alzheimer\u2019s disease: a bibliometric analysis"],"prefix":"10.3389","volume":"18","author":[{"given":"Shengjie","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Shanghai East Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Shanghai East Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Shanghai East Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renlong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Shanghai East Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Shanghai East Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Shanghai East Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/kjm2.12870","article-title":"Advances in blood biomarkers for Alzheimer disease (AD): a review","volume":"40","author":"Assfaw","year":"2024","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1007\/s00415-024-12631-7","article-title":"Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer's disease: a real-world study","volume":"271","author":"Cecchetti","year":"2024","journal-title":"J. Neurol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-024-01459-y","article-title":"Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline","volume":"16","author":"Dark","year":"","journal-title":"Alzheimer's Res. Ther."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/arclin\/acae019","article-title":"Plasma biomarkers for Alzheimer's and related dementias: a review and outlook for clinical neuropsychology","volume":"39","author":"Dark","year":"","journal-title":"Arch. Clin. Neuropsychol."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252010911","article-title":"Blood-based biomarkers in Alzheimer's disease: advancing non-invasive diagnostics and prognostics","volume":"25","author":"Dhauria","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e70060","DOI":"10.1111\/cns.70060","article-title":"The early diagnosis of Alzheimer's disease: blood-based panel biomarker discovery by proteomics and metabolomics","volume":"30","author":"Dong","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e14203","DOI":"10.1002\/alz.14203","article-title":"Paving the way for Alzheimer's disease blood-based biomarkers in primary care","volume":"21","author":"Erickson","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"105405","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform","volume":"109","author":"Feizpour","year":"2024","journal-title":"EBioMedicine"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"8684","DOI":"10.1002\/alz.14318","article-title":"Plasma p-tau181 and GFAP reflect 7T MR-derived changes in Alzheimer's disease: a longitudinal study of structural and functional MRI and MRS","volume":"20","author":"Goschel","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13195-024-01593-7","article-title":"Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study","volume":"16","author":"Gotze","year":"2024","journal-title":"Alzheimer's Res. Ther."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e2235068","DOI":"10.1001\/jamanetworkopen.2022.35068","article-title":"Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers with Race and the role of genetic ancestry, vascular comorbidities, and Neighborhood factors","volume":"5","author":"Hajjar","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e209537","DOI":"10.1212\/WNL.0000000000209537","article-title":"Blood astrocyte biomarkers in Alzheimer disease: a systematic review and Meta-analysis","volume":"103","author":"Holper","year":"2024","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2967\/jnumed.113.120618","article-title":"Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"54","author":"Johnson","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/brain\/awad267","article-title":"The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease","volume":"147","author":"Jung","year":"2024","journal-title":"Brain"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e14458","DOI":"10.1002\/alz.14458","article-title":"Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis","volume":"21","author":"Khalafi","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"17361","DOI":"10.3390\/ijms242417361","article-title":"Blood neurofilament levels predict cognitive decline across the Alzheimer's disease continuum","volume":"24","author":"Lehmann","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/nep3.58","article-title":"Blood-based biomarkers of Alzheimer's disease: standardization and comprehensiveness","volume":"2","author":"Liu","year":"2024","journal-title":"Neuroprotection"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"148812","DOI":"10.1016\/j.brainres.2024.148812","article-title":"Present and future of blood-based biomarkers of Alzheimer's disease: beyond the classics","volume":"1830","author":"Mantellatto","year":"2024","journal-title":"Brain Res."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of Plasma Neurofilament Light with Neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","article-title":"Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort","volume":"271","author":"Mendes","year":"2024","journal-title":"J. Neurol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","article-title":"Alzheimer disease blood biomarkers: considerations for population-level use","volume":"20","author":"Mielke","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.1007\/s00415-024-12674-w","article-title":"Association between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: a systematic review","volume":"271","author":"Mitolo","year":"2024","journal-title":"J. Neurol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","article-title":"Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum","volume":"144","author":"Moscoso","year":"2021","journal-title":"Brain"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/alz.12647","article-title":"Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: important considerations for clinical trials and practice","volume":"19","author":"O'Bryant","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e70828","DOI":"10.1002\/alz.70828","article-title":"Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: a systematic review and meta-analysis","volume":"21","author":"Pahlke","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e70535","DOI":"10.1002\/alz.70535","article-title":"Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s00415-023-12153-8","article-title":"Impact of demographics and comorbid conditions on plasma biomarkers concentrations and their diagnostic accuracy in a memory clinic cohort","volume":"271","author":"Sarto","year":"2024","journal-title":"J. Neurol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","article-title":"Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability","volume":"4","author":"Therriault","year":"2024","journal-title":"Nat. Aging"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","article-title":"Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: results from the standardization of Alzheimer's blood biomarkers (SABB) working group","volume":"18","author":"Verberk","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1002\/alz.13909","article-title":"Plasma amyloid beta X-42\/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease","volume":"20","author":"Vogelgsang","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"102485","DOI":"10.1016\/j.arr.2024.102485","article-title":"CSF and blood glial fibrillary acidic protein for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"101","author":"Zou","year":"2024","journal-title":"Ageing Res. Rev."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1886781\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:11Z","timestamp":1790673911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1886781\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":56,"alternative-id":["10.3389\/fnagi.2026.1886781"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1886781","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1886781"}}